Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › escitalopram

escitalopram

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of escitalopram

75 trials tracked of escitalopram: 56 in phase 3 or 4 and 11 with published results. The most-cited published study has 131 citations.

75Trials tracked
56Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 41 Phase 3 15 Phase 2 7 Other / NA 12
  1. Phase 4 Drug Therapy for Generalized Anxiety Disorder Among the Elderly Completed · 131 cited
  2. Phase 3 Clinical Neurobiology of Serotonin and Addiction Completed · 90 cited
  3. Phase 4 Does Dual Therapy Hasten Antidepressant Response? Completed · 78 cited
  4. Phase 4 Emotional and Cognitive Control in Late-Onset Depression Completed · 72 cited
  5. Phase 4 Brain Aging and Treatment Response in Geriatric Depression Completed · 61 cited
  6. Phase 4 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression Completed · 56 cited
Show 44 more trials
  1. Phase 4 Advancing Personalized Antidepressant Treatment Using PET/MRI Completed · 44 cited
  2. Phase 3 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder Completed · 24 cited
  3. Phase 4 A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder Completed · 21 cited
  4. Phase 4 Connectivity Affecting the Antidepressant REsponse Study Completed · 13 cited
  5. Phase 3 Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) Completed · 13 cited
  6. Phase 4 Characteristics of Sleep Patterns in Young Adults With and Without Insomnia Completed
  7. Phase 4 A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom Completed
  8. Phase 4 Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram Completed
  9. Phase 4 Brain GABA Levels and Treatment Response in Major Depressive Disorder Completed
  10. Phase 4 Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram Completed
  11. Phase 4 Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit Completed
  12. Phase 4 Aging Brain Changes, Executive Dysfunction and Depression Completed
  13. Phase 4 Developing New Clinical Management Strategies Completed
  14. Phase 4 Dichotic Listening as a Predictor of Medication Response in Depression Completed
  15. Phase 4 Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment Completed
  16. Phase 4 Contact: Developing New Clinical Management Strategies Completed
  17. Phase 4 Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits Completed
  18. Phase 4 SSRI Effects on Depression and Immunity in HIV/AIDS Completed
  19. Phase 4 Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder Completed
  20. Phase 4 Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder Completed
  21. Phase 4 Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression Completed
  22. Phase 4 Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression Completed
  23. Phase 4 Escitalopram (Lexapro) for the Treatment of Postpartum Depression Completed
  24. Phase 4 Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment Completed
  25. Phase 4 Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Completed
  26. Phase 4 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed
  27. Phase 4 Brain Effects of Escitalopram and Citalopram Using fMRI Completed
  28. Phase 4 Escitalopram in Patients With Generalized Anxiety Disorder Completed
  29. Phase 4 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed
  30. Phase 4 Depression-Diabetes Mechanisms: Urban African Americans Completed
  31. Phase 4 Influence of Escitalopram on Fear Conditioning Completed
  32. Phase 4 Escitalopram in Patients With Social Anxiety Disorder Completed
  33. Phase 4 A Study of Patients With Major Depressive Disorder and Residual Apathy Completed
  34. Phase 4 Depression, Epinephrine, and Platelet Function Completed
  35. Phase 4 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed
  36. Phase 4 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed
  37. Phase 4 Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder Completed
  38. Phase 4 Responses of Myocardial Ischemia to Escitalopram Treatment Completed
  39. Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder Completed
  40. Phase 3 Study of Neural Responses Induced by Antidepressant Effects Completed
  41. Phase 3 Escitalopram (Lexapro) for Depression MS or ALS Completed
  42. Phase 3 Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction Completed
  43. Phase 3 Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients Completed
  44. Phase 3 Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS Completed

Showing the 50 most-cited and recently-updated of 75 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Fatal serotonin syndrome in Parkinson's patient on rasagiline after sequential SSRI administration
Psychiatry
Fatal serotonin syndrome in Parkinson's patient on rasagiline after sequential SSRI administration Case report describes fatal serotonin syndrome in older Parkinson's patient on multiple medications
A case report describes a 72-year-old Parkinson's patient on rasagiline who developed fatal serotonin syndrome after sequential sertraline a…
A 72-year-old Parkinson's patient died after taking two antidepressants with a genetic makeup that slowed drug processing, causing fatal ser…
Frontiers Apr 1, 2026